Treats primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis…. Sold as Daranide, Keveyis. Every FDA application for this active ingredient: 1 branded and 2 generic.
As of Nov 13, 2026, FDA lists 3 applications for Dichlorphenamide (sold as Daranide, Keveyis), first approved Jul 22, 1958, with 2 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Keveyis | Part D | $26.6M | +13% | 121 |
| Dichlorphenamide | Part D | $846K | +17% | 11 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jul 22, 1958 | Daranide, KeveyisNDA 11366 · New molecular entity | Xeris | 16 | Marketed |
| Dec 29, 2022 | OrmalviANDA 215924 | Torrent | 1 | Marketed |
| Nov 18, 2025 | DichlorphenamideANDA 218783 | Rising | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
